Contraception News and Research

Latest Contraception News and Research

FDA approves update to Rituxan label to include information on treatment of rare forms of vasculitis

Genentech, a member of the Roche Group, announced today that the U.S. Food and Drug Administration has approved an update to the Rituxan® (rituximab) label to include information on follow up treatment of adult patients with Granulomatosis with Polyangiitis and Microscopic Polyangiitis who have achieved disease control with induction treatment.

22 Oct 2018

Exelixis presents CABOSUN and METEOR trial results in patients with advanced renal cell carcinoma

Exelixis, Inc. today announced results from two analyses evaluating the effect of PD-L1 expression or prior treatment with immune checkpoint inhibitors on the efficacy of cabozantinib in patients with advanced renal cell carcinoma (RCC). The findings are being presented this week at the European Society for Medical Oncology 2018 Congress being held October 19-23 in Munich, Germany.

22 Oct 2018

Takeda announces positive Phase 3 ALTA-1L data in first-line therapy for advanced ALK+ NSCLC

Takeda Pharmaceutical Company Limited today announced that intracranial efficacy data from the Phase 3 ALTA-1L (ALK in Lung Cancer Trial of BrigAtinib in 1st Line) trial showed improved intracranial progression-free survival (PFS) and intracranial objective response rate (ORR) with ALUNBRIG (brigatinib) compared to crizotinib among anaplastic lymphoma kinase-positive (ALK+) non-small cell lung cancer (NSCLC) patients.

22 Oct 2018

New family planning app found to be as effective as modern methods

Early results from a first-of-its-kind study suggests that typical use of a family planning app called Dot is as effective as other modern methods for avoiding an unplanned pregnancy.

16 Oct 2018

New 'gag rule' may adversely impact health care of pregnant women

A new Texas Policy Evaluation Project study on Texas organizations receiving family planning funds finds that proposed federal guidelines restricting abortion counseling and referrals for Title X providers may adversely impact the health care of pregnant women.

12 Oct 2018

NCCN adds COPIKTRA capsules to NCCN Guidelines for follicular lymphoma

Verastem, Inc., focused on developing and commercializing medicines to improve the survival and quality of life of cancer patients, today announced that the National Comprehensive Cancer Network added COPIKTRA (duvelisib) capsules to the Clinical Practice Guidelines in Oncology (NCCN Guidelines) for follicular lymphoma.

8 Oct 2018

Phase 3 ECHELON-2 clinical trial evaluating ADCETRIS plus CHP meets primary endpoint

Seattle Genetics, Inc. and Takeda Pharmaceutical Company Limited announced today that the phase 3 ECHELON-2 clinical trial met its primary endpoint.

1 Oct 2018

FDA approves first intravenous treatment for metastatic cutaneous squamous cell carcinoma

The U.S. Food and Drug Administration today approved Libtayo (cemiplimab-rwlc) injection for intravenous use for the treatment of patients with metastatic cutaneous squamous cell carcinoma or locally advanced CSCC who are not candidates for curative surgery or curative radiation.

28 Sep 2018

‘Contraception deserts’ likely to widen under new Trump administration policy

When Nikia Jackson needed to be screened for a sexually transmitted disease, she wanted a clinic that was reputable, quick and inexpensive.

28 Sep 2018

Pfizer announces FDA approval of VIZIMPRO for first-line treatment of EGFR-mutated metastatic NSCLC

Pfizer Inc. today announced that the U.S. Food and Drug Administration has approved VIZIMPRO [vih-ZIM-pro] (dacomitinib), a kinase inhibitor for the first-line treatment of patients with metastatic non-small cell lung cancer with epidermal growth factor receptor exon 19 deletion or exon 21 L858R substitution mutations as detected by an FDA-approved test.

28 Sep 2018

Ovarian cancer risk reduced among women taking modern combined oral contraceptive pills

According to a new study women of reproductive age who are using the modern oral contraceptive pills or patches and rings that contain a combination of estrogen and progesterone are at a reduced risk for ovarian cancer. The study was published in the recent issue of the British Medical Journal (BMJ).

27 Sep 2018

ADCETRIS drug receives approval in Japan as frontline treatment option for Hodgkin lymphoma

Seattle Genetics, Inc. today announced that its collaborator, Takeda Pharmaceutical Company Limited, has received approval from the Japanese Ministry of Health, Labour and Welfare for ADCETRIS (brentuximab vedotin) in combination with doxorubicin, vinblastine and dacarbazine as a frontline treatment option for CD30-positive Hodgkin lymphoma patients in Japan.

24 Sep 2018

CHMP adopts positive opinion of Takeda’s ALUNBRIG for treatment of ALK+ non-small cell lung cancer

Takeda Pharmaceutical Company Limited today announced that the European Medicines Agency's Committee for Medicinal Products for Human Use has adopted a positive opinion, recommending the full approval of ALUNBRIG® as a monotherapy for the treatment of adult patients with anaplastic lymphoma kinase-positive advanced non-small cell lung cancer previously treated with crizotinib.

24 Sep 2018

Ipsen receives approval from Health Canada for CABOMETYX tablets for treating renal cell carcinoma

Exelixis, Inc. today announced that its partner Ipsen Biopharmaceuticals Canada Inc. received approval from Health Canada of CABOMETYX® tablets for the treatment of adults with advanced renal cell carcinoma who have received prior vascular endothelial growth factor targeted therapy.

19 Sep 2018

NCCN updates Clinical Practice Guidelines to include new recommendations for CABOMETYX tablets

Exelixis, Inc. today announced that the National Comprehensive Cancer Network updated its Clinical Practice Guidelines to include new recommendations for CABOMETYX tablets.

7 Sep 2018

Podcast: KHN’s ‘What the Health?’ Health policy goes to court

A federal judge in Texas seemed sympathetic to the argument by GOP state officials that the Affordable Care Act soon will no longer be constitutional since Congress eliminated the penalty for not having insurance. The case was filed by 18 state attorneys general and two governors.

6 Sep 2018

Medicaid expansion may fill gap in reproductive health care access, study finds

Medicaid expansion may fill a significant gap in reproductive health care access, especially among young and low-income women, a new Michigan Medicine study finds.

31 Aug 2018

FDA accepts Bristol-Myers Squibb’s application for Sprycel for treating pediatric leukemia

Bristol-Myers Squibb Company today announced that the U.S. Food and Drug Administration accepted its supplemental Biologics License Application for Sprycel (dasatinib) in combination with chemotherapy for the treatment of pediatric patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia.

30 Aug 2018

Pregnant women with heart disease must give birth at 40 weeks gestation

Pregnant women with heart disease should give birth at no later than 40 weeks gestation. That is one of the recommendations in the 2018 European Society of Cardiology Guidelines for the management of cardiovascular diseases during pregnancy published online today in European Heart Journal, and on the ESC website.

25 Aug 2018

Biorhythms and birth control: FDA stirs debate by approving ‘natural’ app

The Food and Drug Administration took a "big tent" approach earlier this month when it approved two new forms of birth control that prevent pregnancy in very different ways.

21 Aug 2018

Contraception News and Research

Latest Contraception News and Research

FDA approves update to Rituxan label to include information on treatment of rare forms of vasculitis

Exelixis presents CABOSUN and METEOR trial results in patients with advanced renal cell carcinoma

Takeda announces positive Phase 3 ALTA-1L data in first-line therapy for advanced ALK+ NSCLC

New family planning app found to be as effective as modern methods

New 'gag rule' may adversely impact health care of pregnant women

NCCN adds COPIKTRA capsules to NCCN Guidelines for follicular lymphoma

Phase 3 ECHELON-2 clinical trial evaluating ADCETRIS plus CHP meets primary endpoint

FDA approves first intravenous treatment for metastatic cutaneous squamous cell carcinoma

‘Contraception deserts’ likely to widen under new Trump administration policy

Pfizer announces FDA approval of VIZIMPRO for first-line treatment of EGFR-mutated metastatic NSCLC

Ovarian cancer risk reduced among women taking modern combined oral contraceptive pills

ADCETRIS drug receives approval in Japan as frontline treatment option for Hodgkin lymphoma

CHMP adopts positive opinion of Takeda’s ALUNBRIG for treatment of ALK+ non-small cell lung cancer

Ipsen receives approval from Health Canada for CABOMETYX tablets for treating renal cell carcinoma

NCCN updates Clinical Practice Guidelines to include new recommendations for CABOMETYX tablets

Podcast: KHN’s ‘What the Health?’ Health policy goes to court

Medicaid expansion may fill gap in reproductive health care access, study finds

FDA accepts Bristol-Myers Squibb’s application for Sprycel for treating pediatric leukemia

Pregnant women with heart disease must give birth at 40 weeks gestation

Biorhythms and birth control: FDA stirs debate by approving ‘natural’ app

Shaping the Future of Neuroscience: A Conversation with Atlas Antibodies on the MolBoolean™ and the Impact of SfN 2024

How the Arts Reshape Brain Function: Susan Magsamen on the Future of Neuroaesthetics

Inside the Alzheimer's Association: Dr. Heather Snyder on Driving Research and Collaboration

Contraception News and Research

Latest Contraception News and Research

Shaping the Future of Neuroscience: A Conversation with Atlas Antibodies on the MolBoolean™ and the Impact of SfN 2024

How the Arts Reshape Brain Function: Susan Magsamen on the Future of Neuroaesthetics

Inside the Alzheimer's Association: Dr. Heather Snyder on Driving Research and Collaboration

Newsletters you may be interested in